Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples